CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CVRx Secures Devoted Health Coverage for Barostim Therapy
CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches
CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity's 46th Annual Growth Conference.
CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q2 2026 Earnings Call Transcript
CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.57 per share a year ago.
CVRx Q2 Earnings Call Highlights
CVRx NASDAQ: CVRX reported second-quarter revenue growth and an improved gross margin, but lowered its full-year outlook as sales-force turnover, slower productivity ramps and reimbursement challenges with a large Medicare Advantage payer are expected to weigh on results in the second half of 2026.
Compared to Estimates, CVRx (CVRX) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for CVRx (CVRX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
CVRx (CVRX) Moves 11.6% Higher: Will This Strength Last?
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRx Stock Up on Humana's Medicare Coverage for Barostim Therapy
CVRX stock gains after Humana adds Medicare Advantage coverage for Barostim therapy, boosting reimbursement momentum and patient access.
Down 31.7% in 4 Weeks, Here's Why You Should You Buy the Dip in CVRx (CVRX)
CVRx (CVRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx, Inc. (CVRX) Q1 2026 Earnings Call Transcript
CVRx Q1 Earnings Call Highlights
CVRx NASDAQ: CVRX reported first-quarter 2026 revenue of $14.8 million, up 20% from the prior-year period, as U.S. growth in its Barostim heart failure business helped the company exceed the high end of its guidance range, executives said on the company's earnings call.
CVRx (CVRX) Reports Q1 Loss, Beats Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.53 per share a year ago.
